Talaris Therapeutics Statistics
Share Statistics
Talaris Therapeutics has 42.81M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 42.81M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 12,694 |
| FTD / Avg. Volume | 8.88% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.06 and the forward
PE ratio is null.
Talaris Therapeutics's PEG ratio is
-0.08.
| PE Ratio | -0.06 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.02 |
| P/FCF Ratio | -0.07 |
| PEG Ratio | -0.08 |
Financial Ratio HistoryEnterprise Valuation
Talaris Therapeutics has an Enterprise Value (EV) of -6.58M.
| EV / Sales | 0 |
| EV / EBITDA | 0.09 |
| EV / EBIT | 0.11 |
| EV / FCF | 0.1 |
Financial Position
The company has a current ratio of 16.19,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 16.19 |
| Quick Ratio | 16.19 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.05 |
| Interest Coverage | -29.61 |
Financial Efficiency
Return on Equity is -38.17% and Return on Invested Capital is -38.88%.
| Return on Equity | -38.17% |
| Return on Assets | -35.48% |
| Return on Invested Capital | -38.88% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-818,190.48 |
| Employee Count | 84 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.17M |
| Effective Tax Rate | 6.99% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 2.18, so Talaris Therapeutics's
price volatility has been higher than the market average.
| Beta | 2.18 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.83 |
| 200-Day Moving Average | 2.41 |
| Relative Strength Index (RSI) | 46.62 |
| Average Volume (20 Days) | 142,922 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -76.48M |
| Net Income | -68.73M |
| EBITDA | -74.31M |
| EBIT | -71.31M |
| Earnings Per Share (EPS) | -16.66 |
Full Income StatementBalance Sheet
The company has 13.67M in cash and 2.88M in
debt, giving a net cash position of 10.79M.
| Cash & Cash Equivalents | 13.67M |
| Total Debt | 2.88M |
| Net Cash | 10.79M |
| Retained Earnings | -164.74M |
| Total Assets | 151.06M |
| Working Capital | 142.94M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -60.86M
and capital expenditures -3.04M, giving a free cash flow of -63.9M.
| Operating Cash Flow | -60.86M |
| Capital Expenditures | -3.04M |
| Free Cash Flow | -63.9M |
| FCF Per Share | -15.49 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
